These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 1730728

  • 1. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia.
    Horie Y, Fazio S, Westerlund JR, Weisgraber KH, Rall SC.
    J Biol Chem; 1992 Jan 25; 267(3):1962-8. PubMed ID: 1730728
    [Abstract] [Full Text] [Related]

  • 2. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.
    März W, Hoffmann MM, Scharnagl H, Fisher E, Chen M, Nauck M, Feussner G, Wieland H.
    J Lipid Res; 1998 Mar 25; 39(3):658-69. PubMed ID: 9548597
    [Abstract] [Full Text] [Related]

  • 3. Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.
    Wardell MR, Rall SC, Brennan SO, Nye ER, George PM, Janus ED, Weisgraber KH.
    J Lipid Res; 1990 Mar 25; 31(3):535-43. PubMed ID: 2341812
    [Abstract] [Full Text] [Related]

  • 4. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.
    Ji ZS, Fazio S, Mahley RW.
    J Biol Chem; 1994 May 06; 269(18):13421-8. PubMed ID: 8175773
    [Abstract] [Full Text] [Related]

  • 5. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy.
    Hoffmann MM, Scharnagl H, Panagiotou E, Banghard WT, Wieland H, März W.
    J Am Soc Nephrol; 2001 Mar 06; 12(3):524-530. PubMed ID: 11181800
    [Abstract] [Full Text] [Related]

  • 6. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia.
    Mann WA, Meyer N, Weber W, Meyer S, Greten H, Beisiegel U.
    J Lipid Res; 1995 Mar 06; 36(3):517-25. PubMed ID: 7775863
    [Abstract] [Full Text] [Related]

  • 7. Apolipoprotein E2(Arg158----Cys) frequency in a hyperlipidemic French-Canadian population of apolipoprotein E2/2 subjects. Determination by synthetic oligonucleotide probes.
    Weisgraber KH, Newhouse YM, Taylor JM, Tuan B, Nestruck AC, Davignon J, Mahley RW.
    Arteriosclerosis; 1989 Mar 06; 9(1):50-7. PubMed ID: 2912421
    [Abstract] [Full Text] [Related]

  • 8. Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu).
    Mann WA, Lohse P, Gregg RE, Ronan R, Hoeg JM, Zech LA, Brewer HB.
    J Clin Invest; 1995 Aug 06; 96(2):1100-7. PubMed ID: 7635945
    [Abstract] [Full Text] [Related]

  • 9. The carboxyl terminus in apolipoprotein E2 and the seven amino acid repeat in apolipoprotein E-Leiden: role in receptor-binding activity.
    Dong LM, Innerarity TL, Arnold KS, Newhouse YM, Weisgraber KH.
    J Lipid Res; 1998 Jun 06; 39(6):1173-80. PubMed ID: 9643348
    [Abstract] [Full Text] [Related]

  • 10. A novel electrophoretic variant of human apolipoprotein E. Identification and characterization of apolipoprotein E1.
    Weisgraber KH, Rall SC, Innerarity TL, Mahley RW, Kuusi T, Ehnholm C.
    J Clin Invest; 1984 Apr 06; 73(4):1024-33. PubMed ID: 6323533
    [Abstract] [Full Text] [Related]

  • 11. Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia.
    Havekes L, de Wit E, Leuven JG, Klasen E, Utermann G, Weber W, Beisiegel U.
    Hum Genet; 1986 Jun 06; 73(2):157-63. PubMed ID: 3721502
    [Abstract] [Full Text] [Related]

  • 12. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatin.
    Zhao SP, Smelt AH, Van den Maagdenberg AM, Van Tol A, Vroom TF, Gevers Leuven JA, Frants RR, Havekes LM, Van der Laarse A, Van 't Hooft FM.
    Arterioscler Thromb; 1994 Nov 06; 14(11):1705-16. PubMed ID: 7947593
    [Abstract] [Full Text] [Related]

  • 13. Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions.
    Lalazar A, Weisgraber KH, Rall SC, Giladi H, Innerarity TL, Levanon AZ, Boyles JK, Amit B, Gorecki M, Mahley RW.
    J Biol Chem; 1988 Mar 15; 263(8):3542-5. PubMed ID: 2831187
    [Abstract] [Full Text] [Related]

  • 14. Familial dysbetalipoproteinemia: a genetically heterogenous disease caused by mutations of the ligand apolipoprotein E.
    Vermeer BJ, Frants RR, Havekes LM.
    J Invest Dermatol; 1992 Jun 15; 98(6 Suppl):57S-60S. PubMed ID: 1588125
    [Abstract] [Full Text] [Related]

  • 15. Compound heterozygote for both rare apolipoprotein E1 (Gly127-->Asp, Arg158-->Cys) and E3(Cys112-->Arg, Arg251-->Gly) alleles in a multigeneration pedigree with hyperlipoproteinaemia.
    Richard P, Beucler I, Pascual De Zulueta M, Biteau N, De Gennes JL, Iron A.
    Clin Sci (Lond); 1997 Jul 15; 93(1):89-95. PubMed ID: 9279208
    [Abstract] [Full Text] [Related]

  • 16. Apolipoprotein E2 (Arg-136-->Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia.
    Feussner G, Albanese M, Mann WA, Valencia A, Schuster H.
    Eur J Clin Invest; 1996 Jan 15; 26(1):13-23. PubMed ID: 8682150
    [Abstract] [Full Text] [Related]

  • 17. Apolipoprotein E-1Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia.
    Mann WA, Gregg RE, Sprecher DL, Brewer HB.
    Biochim Biophys Acta; 1989 Oct 17; 1005(3):239-44. PubMed ID: 2804053
    [Abstract] [Full Text] [Related]

  • 18. Genetic polymorphism of apolipoprotein E: a variant form of apolipoprotein E2 distinguished by sodium dodecyl sulfate--polyacrylamide gel electrophoresis.
    Utermann G, Weisgraber KH, Weber W, Mahley RW.
    J Lipid Res; 1984 Apr 17; 25(4):378-82. PubMed ID: 6726088
    [Abstract] [Full Text] [Related]

  • 19. Association of human, rat, and rabbit apolipoprotein E with beta-amyloid.
    LaDu MJ, Lukens JR, Reardon CA, Getz GS.
    J Neurosci Res; 1997 Jul 01; 49(1):9-18. PubMed ID: 9211985
    [Abstract] [Full Text] [Related]

  • 20. Heterozygosity for apolipoprotein E-4Philadelphia(Glu13----Lys, Arg145----Cys) is associated with incomplete dominance of type III hyperlipoproteinemia.
    Lohse P, Rader DJ, Brewer HB.
    J Biol Chem; 1992 Jul 05; 267(19):13642-6. PubMed ID: 1352296
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.